Geratos Injection

Adult administration

In adults, administer 500-1,000mL by slow intravenous infusion. The infusion rate should not exceed 0.5g of fructose per kilogram of body weight per hour. Adjust the dosage and infusion rate appropriately according to age, weight, and symptoms.

This drug should not be used with ceftriaxone, as calcium precipitates may form when administered intravenously using the same infusion equipment. Allergic reactions may occur when this drug is administered; therefore, administration should be immediately stopped and appropriate treatment sought if allergic symptoms appear. This drug contains a high level of potassium, which may increase serum potassium levels and risk of hyperkalemia; thus, patients with poor kidney function or heart disease should exercise caution and frequently monitor their serum potassium levels. Due to the presence of glucose, diabetic patients or those who have difficulty controlling blood sugar levels may experience elevated blood sugar, and should regularly check their blood sugar and consider insulin therapy if needed. Increased sodium and chloride levels may lead to hypernatremia or hyperchloremia. Patients with heart or liver diseases should carefully consider use prior to administration and monitor electrolyte levels and kidney function. Conversely, this drug may induce hyponatremia, so children, the elderly, patients after surgery, or those taking certain medications should frequently check serum sodium levels. Severe hyponatremia may present with symptoms such as headache, vomiting, and seizures. Hypercalcemia may occur due to elevated calcium levels, so patients with calcium kidney stones or those at risk for hypercalcemia should avoid administration. This drug may cause fluid overload; therefore, patients with heart failure or edema should regulate the dosage and rate of administration while closely monitoring their fluid status. This drug should not be administered to patients with hereditary fructose intolerance, storage dehydration, hypernatremia, hyperglycemia, and to neonates. Patients with severe renal impairment, heart failure, hyperosmolar dehydration, obstructive uropathy, diabetes insipidus, hyperchloremia, or hyponatremia should be carefully monitored during administration. Rapid administration of this drug may cause severe side effects such as cerebral edema, pulmonary edema, and peripheral edema, so it should be administered slowly. Regular monitoring of blood sugar, electrolytes, and fluid balance is important, especially for patients taking medications that may interact with this drug. During pregnancy, this drug poses risks to the fetus and should only be used if absolutely necessary. Neonates and children should be closely monitored for blood sugar and electrolyte levels. This drug should not be used in combination with preparations containing phosphate or carbonate, and prior to administration, the patient's skin and the infusion device should be thoroughly disinfected and warmed to body temperature.

Serious side effects

• Hives
• anaphylaxis
• severe swelling (edema)
• respiratory distress
• cardiac arrest
• hyponatremic encephalopathy
• pulmonary edema
• cerebral edema.

Mild side effects

• Vomiting
• hypertension
• tachycardia
• fever
• sweating
• flushing
• chills
• infusion site blisters
• extravasation
• venous thrombosis

This drug must be stored in a sealed container to prevent exposure to air and should be kept at a temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the drug's efficacy and prevents deterioration.

Appearance

A colorless or slightly yellow, transparent injection solution in a colorless, transparent multi-layer film plastic and polypropylene aqueous injection container

Package unit

500mL/pack